Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of “Buy” from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $6.88.

A number of research firms have recently commented on TSHA. Chardan Capital raised their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, March 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 18th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Piper Sandler started coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 price objective on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st.

Taysha Gene Therapies Stock Down 7.1 %

TSHA opened at $2.35 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The business has a 50 day simple moving average of $2.61 and a 200-day simple moving average of $2.09. The stock has a market capitalization of $439.50 million, a P/E ratio of -3.51 and a beta of 0.29. Taysha Gene Therapies has a 12 month low of $0.50 and a 12 month high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. On average, equities analysts anticipate that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Investment Advisors LLC acquired a new stake in shares of Taysha Gene Therapies in the third quarter worth $32,000. Commonwealth Equity Services LLC grew its position in shares of Taysha Gene Therapies by 44.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 26,971 shares of the company’s stock worth $85,000 after buying an additional 8,246 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $82,000. Chicago Partners Investment Group LLC acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $351,000. Finally, TD Asset Management Inc acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $555,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.